Literature DB >> 29575677

Vitamin D Analogues Tacalcitol and Calcipotriol Inhibit Proliferation and Migration of T98G Human Glioblastoma Cells.

Ida Emanuelsson1, Kjell Wikvall1, Tomas Friman1, Maria Norlin1.   

Abstract

The active form of vitamin D (1α,25-dihydroxyvitamin D) acts as a steroid hormone and binds to the vitamin D receptor. This receptor is expressed in most cell types including cells in the central nervous system (CNS). Vitamin D has several functions in the body including effects on brain development, neuroprotection and immunological regulation. It has been shown that vitamin D has antiproliferative activities in different cancer cell lines. Tacalcitol and calcipotriol are synthetic analogues of 1α,25-dihydroxyvitamin D with reduced effect on calcium metabolism. The aim of this study was to analyse the effects of tacalcitol and calcipotriol on cell viability, proliferation and migration in the human glioblastoma cell line T98G. Glioblastoma is the most lethal type of primary tumours in the CNS. Both analogues decreased cell viability and/or growth, dose-dependently, in concentrations between 1 nM and 10 μM. Manual counting indicated suppressive effects by the vitamin D analogues on proliferation. Treatment with tacalcitol strongly suppressed thymidine incorporation, indicating that the vitamin D analogues mainly inhibit proliferation. Also, effects on cell migration were measured with wound-healing assay. Both calcipotriol and tacalcitol reduced the migration rate of T98G cells compared to vehicle-treated cells. However, they had no effect on caspase-3 and -7 activities, suggesting that their mechanism of action does not involve induction of apoptosis. The current results indicate that the vitamin D analogues tacalcitol and calcipotriol strongly reduce proliferation and migration of human glioblastoma T98G cells, suggesting a potential role for this type of compounds in treatment of brain cancer.
© 2018 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29575677     DOI: 10.1111/bcpt.13007

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  7 in total

Review 1.  Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Authors:  Amandeep Thakur; Chetna Faujdar; Ram Sharma; Sachin Sharma; Basant Malik; Kunal Nepali; Jing Ping Liou
Journal:  J Med Chem       Date:  2022-07-05       Impact factor: 8.039

Review 2.  Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities.

Authors:  Romina Kohan; Alejandro Collin; Solange Guizzardi; Nori Tolosa de Talamoni; Gabriela Picotto
Journal:  Cancer Chemother Pharmacol       Date:  2020-06-22       Impact factor: 3.333

Review 3.  Daily Lifestyle Modifications to Improve Quality of Life and Survival in Glioblastoma: A Review.

Authors:  Sarah Travers; N Scott Litofsky
Journal:  Brain Sci       Date:  2021-04-23

Review 4.  Anti-tumor effects of vitamin D in glioblastoma: mechanism and therapeutic implications.

Authors:  Carmen Sze-Ching Lo; Karrie Mei-Yee Kiang; Gilberto Ka-Kit Leung
Journal:  Lab Invest       Date:  2021-09-09       Impact factor: 5.662

5.  Association of Methylenetetrahydrofolate Reductase, Vitamin D Receptor, and Interleukin-16 Gene Polymorphisms With Renal Cell Carcinoma Risk.

Authors:  Tianbiao Zhou; Hongyan Li; Wei-Ji Xie; Zhiqing Zhong; Hongzhen Zhong; Zhi-Jun Lin
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

6.  Effects of 1α,25-dihydroxyvitamin D3 and tacalcitol on cell signaling and anchorage-independent growth in T98G and U251 glioblastoma cells.

Authors:  Frida Olsson; Niki Sarri; Natalia Papadopoulos; Johan Lennartsson; Maria Norlin
Journal:  Biochem Biophys Rep       Date:  2022-07-31

7.  Design and Development of Gold-Loaded and Boron-Attached Multicore Manganese Ferrite Nanoparticles as a Potential Agent in Biomedical Applications.

Authors:  Okan Icten; Beril Erdem Tuncdemir; Hatice Mergen
Journal:  ACS Omega       Date:  2022-06-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.